Companies Dominating the Hormone Replacement Therapy Landscape
- AbbVie Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Abbott Laboratories
- Novo Nordisk A/S
- Genentech, Inc.
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Merck KGaA
- Mylan N.V.
- Bayer AG
- Eli Lilly and Company
Browse Key Market Insights with Data Illustration:
In the News
-
Orion Pharma AB to acquire the clearance for darolutamide indication in the combination with docetaxel from U.S. Food and Drug Administration (FDA). The product is developed for the treatment of metastatic hormone-sensitive prostate cancer shortly known as (mHSPC).
-
Genentech, Inc. to release positive results from the Phase III SKYSCRAPER-01 study. The study was being conducted to monitor the anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) vs Tecentriq alone as an initial (first-line) to find the cure for people living with advanced or metastatic non-small cell lung cancer (NSCLC).
